The current public health war against bacterial infections is rapidly approaching a critical stage, in which bacterial resistance to antibiotics becomes widespread and our reservoirs of available antibiotics and viable therapeutics are depleted. During the past 60 years, the rise in the frequency of resistance, particularly to multiple drugs, has thwarted the treatment of patients in the hospital and the community. According to Rabih Darouiche, MD of Baylor College of Medicine, microbial resistance is emerging faster than we are replacing our armamentarium of antimicrobial agents.
Dr. Darouiche, in collaboration with the product development team from NovaBay Pharmaceuticals, recently published a monograph on NovaBay’s lead Aganocide® NVC-422 in the journal Drugs of the Future. Newswise
No comments:
Post a Comment